Cancer Drug CUE-101 Achieves 50% Response Rate in Head and Neck Cancer Trial - Stock Titan

Retrieved on: 2025-07-16 20:13:19

Tags for this article:

Click the tags to see associated articles and topics

Cancer Drug CUE-101 Achieves 50% Response Rate in Head and Neck Cancer Trial - Stock Titan. View article details on hiswai:

Excerpt

Oncology Clinical Trials Expert positive. Cue Biopharma's CUE-101 shows impressive 50% response rate and 32-month survival in HPV+ head/neck ...

Article found on: www.stocktitan.net